au.\*:("MOM, C. H")
Results 1 to 1 of 1
Selection :
A phase I dose escalation study off BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumoursESKENS, F. A. L. M; MOM, C. H; DE VRIES, E. G. E et al.British journal of cancer. 2008, Vol 98, Num 1, pp 80-85, issn 0007-0920, 6 p.Article
